Capricor TherapeuticsCAPR
CAPR
About: Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Employees: 160
0
Funds holding %
of 7,430 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
8% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 37
10.15% less ownership
Funds ownership: 40.11% [Q1] → 29.96% (-10.15%) [Q2]
12% less funds holding
Funds holding: 120 [Q1] → 106 (-14) [Q2]
22% less call options, than puts
Call options by funds: $47.4M | Put options by funds: $60.7M
22% less capital invested
Capital invested by funds: $174M [Q1] → $136M (-$37.9M) [Q2]
39% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 28
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
84%
upside
Avg. target
$22
231%
upside
High target
$29
344%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Roth Capital Boobalan Pachaiyappan | 84%upside $12 | Buy Maintained | 14 Jul 2025 |
HC Wainwright & Co. Joseph Pantginis | 268%upside $24 | Buy Maintained | 11 Jul 2025 |
B. Riley Securities Madison El-Saadi | 222%upside $21 | Buy Initiated | 26 Jun 2025 |
Jones Trading Catherine Novack | 344%upside $29 | Buy Maintained | 25 Jun 2025 |
Oppenheimer Leland Gershell | 237%upside $22 | Outperform Maintained | 23 Jun 2025 |
Financial journalist opinion
Based on 91 articles about CAPR published over the past 30 days
Neutral
PRNewsWire
1 hour ago
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025.
Neutral
PRNewsWire
8 hours ago
CAPR Stockholders with Large Losses Should Contact Robbins LLP Before the Lead Plaintiff Deadline for Information About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit
SAN DIEGO , Aug. 26, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
Neutral
Business Wire
15 hours ago
CAPR INVESTORS: Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)---- $CAPR #classactionlawsuit--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities during the period of October 9, 2024 through July 10, 2025 inclusive (“the Class Period”). If you suffered a loss on your Capricor investments, you have until September 15, 2025 to request lead plaintiff appointment. Follow the link below for more information: [C.
Neutral
GlobeNewsWire
15 hours ago
September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.
Neutral
GlobeNewsWire
23 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Neutral
PRNewsWire
1 day ago
Contact The Gross Law Firm by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)
NEW YORK , Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
GlobeNewsWire
1 day ago
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR)
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ CAPR)
Neutral
GlobeNewsWire
2 days ago
CAPR DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CAPR
NEW YORK, Aug. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline.
Neutral
PRNewsWire
3 days ago
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK , Aug. 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"), of the important September 15, 2025 lead plaintiff deadline. So what: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
GlobeNewsWire
3 days ago
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights – CAPR
NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.
Charts implemented using Lightweight Charts™